Abstracts tagged "osteoporosis"

Abstract Number: 1999 • ACR Convergence 2023
One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation
Cristina Rodríguez-Alvear¹, Mª Carmen López-González², Elisabet Perea-Martínez³, Antonio Avilés-Hernández³, Irene Calabuig-Sais¹, Maria-Luisa Peral-Garrido⁴, Pilar Bernabeu-Gonzálvez³, Agustín Martínez-Sanchís¹, Joaquim Esteve-Vives³, PALOMA VELA⁵, Cayetano Miralles Maciá³, Vega Jovani⁶ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²General University Hospital Dr. Balmis, Alacante, Spain, ³General University Hospital Dr. Balmis, Alicante, Spain, ⁴Vinalopó University Hospital, Novelda, Spain, ⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁶Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain
Background/Purpose: In solid organ transplantation, liver transplants are among those most frequently associated with the development of low bone mass, which occurs in up to…
Abstract Number: 2016 • ACR Convergence 2023
Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis
Moritz Pfeiffenberger¹, Johannes Plank¹, Alexandra Damerau¹, Timo Gaber¹ and Frank Buttgereit², ¹Charité Universitatsmedizine - Berlin, Berlin, Germany, ²Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, leading to pain and reduced mobility in patients. Glucocorticoid-induced…
Abstract Number: 2000 • ACR Convergence 2023
Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study
Mai Kawazoe¹, Kaichi Kaneko², Shotaro Masuoka³, Soichi yamada³, Zento Yamada³, Sei Muraoka³, Karin Furukawa¹, Hiroshi Sato³, Eri Watanabe³, Keiko Koshiba³, Izumi Irita³, Miwa Kanaji³ and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ³Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…
Abstract Number: 2017 • ACR Convergence 2023
Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher³, Andriko Palmowski⁴, Zhivana Boyadzhieva⁵, Sandra Hermann¹, Burkhard Muche¹, Tobias Alexander⁶, Falk Hiepe⁵ and Frank Buttgereit¹, ¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁶Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for osteoporosis and fragility fractures. This risk is mediated by a variety of factors…
Abstract Number: L01 • ACR Convergence 2022
Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
Giovanni Adami, Angelo Fassio, Davide Bertelle, Camilla Benini, Davide Gatti and Maurizio Rossini, Rheumatology Unit, University of Verona, Verona, Italy
Background/Purpose: The recently published GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial has opened the debate around the benefits of glucocorticoids (GCs) in older patients with…
Abstract Number: L11 • ACR Convergence 2022
Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial
Wai Han Ma¹, Chi Chiu Mok², Ling Yin Ho², Kar Li Chan³, Sau Mei Tse⁴ and Sammy Chen⁵, ¹Department of Nuclear Medicine, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Tsing Yi, Hong Kong, ⁴Department of Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ⁵Department of Pathology, Hong Kong, Hong Kong
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients with glucocorticoid -induced osteoporosis (GIOP)Methods: Adult patients (≥18 years)…
Abstract Number: 0502 • ACR Convergence 2022
The Effect of Osteoporosis on Developing Vertebral Compression Fracture After Single-level Posterior Lumbar Fusion Surgery: A Large Healthcare Claims Database Study
Vartika Kesarwani¹, Sean Esmende², Regina Kostyun², Matthew Solomito², Heeren Makanji², John Magaldi² and Mandeep Kumar², ¹University of Connecticut, Farmington, CT, ²Bone and Joint Institute, Hartford Hospital, Hartford, CT
Background/Purpose: Vertebral compression fracture (VCF) is a significant osteoporosis-related complication (ORC) associated with instrumented spinal fusion. Various studies have assessed the development of VCF in…
Abstract Number: 1310 • ACR Convergence 2022
Is the Trabecular Bone Score (TBS) a Useful Tool in Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
Bjoern Buehring¹, David Kiefer², Celina Mueller², Roshnak Parvaee², Marianti Ifanti², Ioana Andreica³, Timm Westhoff⁴, Rainer Wirth⁴, Xenofon Baraliakos⁵, Nina Babel⁴ and Juergen Braun², ¹Bergisches Rheuma-Zentrum, Wuppertal, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMD) have an increased fracture risk (FxR). Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory disease characterized by…
Abstract Number: 1331 • ACR Convergence 2022
Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
Felipe Freire da Silva¹, Gisela Machado², ana Medeiros³, Karina Bonfiglioli⁴, Andrea Shimabuco², Liliam Takayama⁵, Rosa Pereira⁶ and Diogo Domiciano⁷, ¹FMUSP, Salvador, Brazil, ²FMUSP, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil, ⁴Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵University of São Paulo, São Paulo, Brazil, ⁶Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low bone mineral density (BMD) is a predictor of osteoporotic fracture. However, individuals with Rheumatoid Arthritis (RA) who sustain "osteoporosis-related" fractures frequently have normal…
Abstract Number: 0574 • ACR Convergence 2022
Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity
Arash Mollaeian¹ and Stanley Ballou², ¹Metro Health Medical Center/Case Western Reserve University, Rocky River, OH, ²Case Western Reserve University - Metro Health, Cleveland, OH
Background/Purpose: 20-25% of osteoporosis-related fractures occur in men and the mortality of osteoporotic fractures is higher in men [1]. Nevertheless, no uniform consensus exists for…
Abstract Number: 1312 • ACR Convergence 2022
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Leny Pearman⁴, jake Mathew⁴, Yamei Wang⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Waltham, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
Abstract Number: 1338 • ACR Convergence 2022
Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis
Sagarika Dey¹, Gloria Spratt², Muguet Koobasi³, Carol Vleeskens⁴, Carlos El-Haddad⁵ and Ayano Kelly⁶, ¹School of Clinical Medicine, South Western Sydney Campus, University of New South Wales, Parramatta, New South Wales, Australia, ²Physiotherapy Department and Rheumatology Department, Liverpool Hospital; Zone34 Sports Physiotherapy, Liverpool, Australia, ³Knowledge Centre for Health Ghent, Ghent University, Ghent, Belgium, ⁴Sydney Partnership for Health Medical Research and Enterprise Consumer Community Council, Liverpool, Australia, ⁵Rheumatology Department, Liverpool Hospital, Liverpool, Australia, ⁶South Western Sydney Campus, UNSW Medicine & Health, Braddon, Australia
Background/Purpose: Suboptimal adherence to anti-osteoporotic medications presents a growing social and economic concern. Yet, it is unclear what patients' perspectives and experiences are regarding medication…
Abstract Number: 0575 • ACR Convergence 2022
Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis
Leslie Spangler¹, Carrie Nielson¹, M Alan Brookhart², Rohini K Hernandez¹, Robert Kees Stad³ and Jay Lin¹, ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland
Background/Purpose: There has been inconsistent evidence published regarding the cardio- and cerebrovascular benefits and risks of anti-osteoporosis medications. EU regulators requested Amgen to evaluate the…
Abstract Number: 1313 • ACR Convergence 2022
The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study
Laura Carbone¹, Petra Bůžková², John Robbins³, Howard Fink⁴, Joshua Barzilay⁵, Rachel Elam¹ and Carlos Isales¹, ¹Augusta University, Augusta, GA, ²University of Washington, Seattle, WA, ³UC Davis, Davis, CA, ⁴University of Minnesota, Minneapolis, MN, ⁵Kaiser Permanente, Atlanta, GA
Background/Purpose: Essential amino acids including tryptophan (trp) are building blocks for protein, and adequate protein intake is important for skeletal homeostasis. In experimental studies, trp…
Abstract Number: 1477 • ACR Convergence 2022
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Hospital Authority, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors of fragility fractures in a longitudinal cohort of patients with SLE.Methods: All patients who fulfilled ≥4 1997…

« Previous Page
1
…
5
6
7
8
9
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].